Louisiana State Employees Retirement System Takes $1.80 Million Position in Repligen Corporation $RGEN

Louisiana State Employees Retirement System acquired a new position in Repligen Corporation (NASDAQ:RGEN) during the first quarter, HoldingsChannel.com reports. The fund acquired 15,300 shares of the biotechnology company’s stock, valued at approximately $1,803,000.

Several other large investors have also added to or reduced their stakes in the business. Bayforest Capital Ltd bought a new position in Repligen in the fourth quarter valued at $32,000. Rachor Investment Advisory Services LLC bought a new stake in Repligen during the 4th quarter worth about $33,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Repligen during the 3rd quarter worth about $29,000. Los Angeles Capital Management LLC acquired a new position in shares of Repligen during the 4th quarter worth about $36,000. Finally, Farther Finance Advisors LLC grew its holdings in shares of Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 128 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

NASDAQ:RGEN opened at $136.44 on Wednesday. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The stock’s 50 day moving average price is $123.14 and its two-hundred day moving average price is $135.00. The firm has a market capitalization of $7.70 billion, a price-to-earnings ratio of 151.60, a P/E/G ratio of 2.64 and a beta of 1.09. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $175.77.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same period last year, the firm posted $0.39 earnings per share. The business’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of recent research reports. Barclays lifted their target price on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Rothschild & Co Redburn set a $160.00 price target on Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Royal Bank Of Canada initiated coverage on shares of Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price for the company. Roth Mkm started coverage on shares of Repligen in a report on Friday, April 17th. They set a “buy” rating and a $160.00 target price on the stock. Finally, JPMorgan Chase & Co. dropped their price target on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $164.64.

Insider Transactions at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.60% of the stock is owned by corporate insiders.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.